Developer docs
API playgroundTry for free, no card

Search company profiles

Breathe BioMedical

Full company profile

uuid000ctdw

Namestring
Breathe BioMedical
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Breathe BioMedical is a privately held Canadian health-technology company headquartered in Moncton, New Brunswick, that describes its offering as a technology platform for cancer screening through breath analysis. The company's value proposition, as captured in firmographics, is non-invasive cancer detection via exhaled breath, positioning it in the breathomics / liquid-biopsy-adjacent diagnostics category rather than imaging or blood-based screening.

The firm operates with a headcount in the 11–50 range and is at an early commercial stage. The source materials did not surface product-level detail — no sensor architecture, biomarker panel, clinical validation results, regulatory submissions, or named partner institutions were disclosed. The company website returned only a loading/verification page at the time of scraping, so technical and commercial specifics are not verifiable from the input. No certifications, patents, partnerships, leadership team, customers, or pricing information were available.

No revenue, pricing model, or go-to-motion data were disclosed. The financial figures in the source (EBITDA, operating income, net income reported in the trillions of dollars) are not credible for an 11–50-person startup and appear to be data extraction errors rather than actual reported results; they should not be relied upon. As a result, revenue mechanics, customer segments, and contract economics cannot be characterized with any confidence from this dataset.

Short descriptiontext

Breathe BioMedical is a privately held Canadian health-technology company in Moncton that develops a breath-analysis platform for non-invasive cancer screening, currently operating at an early stage with 11–50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMoncton, Canada
HQ citystring
Moncton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
breath analysis diagnostics, cancer screening technology, non-invasive diagnostics, biomedical platform, volatile organic compound detection
Industry1 code
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Diagnostics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Breathe BioMedical is a technology platform that provides cancer screening through breath analysis. The company analyzes breath samples using its proprietary biomedical platform to enable non-invasive detection of cancer, offering an alternative to traditional tissue biopsy or imaging-based screening methods.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Cancer Screening via Breath Analysis Platform
CategoryCancer Diagnostics
Description

A technology platform that performs cancer screening by analyzing breath samples, offered to healthcare providers, clinical laboratories, and cancer screening programs as a non-invasive alternative to traditional diagnostic methods.

No data
Peers10 records
TypeEmerging player
Description

Aethon is pursuing breath-based biomarker detection for lung cancer, a direct indication overlap with Breathe BioMedical's cancer-screening focus.

2GRAIL
TypeBroad incumbent
Description

GRAIL is the leading multi-cancer early-detection company (Galleri test) and represents the dominant non-invasive screening competitor that any breath-based cancer platform must position against.

TypeDirect peer
Description

Menssana Research pioneered clinical breath-testing for disease detection, sharing the core value proposition of non-invasive breath-based diagnostics with Breathe BioMedical.

TypeEmerging player
Description

Cairn Diagnostics develops breath-based diagnostic tests for metabolic and GI conditions, sharing the breath-sample collection and analysis model used by Breathe BioMedical.

TypeEmerging player
Description

Bioserenity focuses on connected diagnostic and monitoring solutions including breath-related respiratory diagnostics, making it a comparable emerging player in non-invasive diagnostic technology.

TypeDirect peer
Description

Owlstone Medical is the leading commercial-stage developer of breath-based diagnostics ('Breath Biopsy') for cancer and other diseases, making it the closest direct competitor and most comparable peer to Breathe BioMedical.

7Xhale
TypeDirect peer
Description

Xhale develops breath-based diagnostic and monitoring technologies, overlapping directly with Breathe BioMedical's breath-analysis modality.

TypeDirect peer
Description

Avisa is developing breath-based biomarker tests for detecting pulmonary and other infections, directly overlapping with Breathe BioMedical's breath-analysis diagnostic approach.

TypeBroad incumbent
Description

Thermo Fisher's diagnostics segment provides mass spectrometry and lab services that underpin clinical biomarker detection, including breath biomarker workflows; a broad incumbent that could partner with or acquire niche players like Breathe BioMedical.

10Exhalation Technology (e.g., Sensity AI)
TypeEmerging player
Description

Sensity AI applies AI to volatile organic compound (VOC) analysis from breath, sharing the machine-learning-on-breath-signals approach underpinning many cancer-screening platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Breathe BioMedical

Cancer Diagnosticsbreathebiomedical.com

Breathe BioMedical is a privately held Canadian health-technology company in Moncton that develops a breath-analysis platform for non-invasive cancer screening, currently operating at an early stage with 11–50 employees.

What Breathe BioMedical does

Breathe BioMedical is a privately held Canadian health-technology company headquartered in Moncton, New Brunswick, that describes its offering as a technology platform for cancer screening through breath analysis. The company's value proposition, as captured in firmographics, is non-invasive cancer detection via exhaled breath, positioning it in the breathomics / liquid-biopsy-adjacent diagnostics category rather than imaging or blood-based screening.

The firm operates with a headcount in the 11–50 range and is at an early commercial stage. The source materials did not surface product-level detail — no sensor architecture, biomarker panel, clinical validation results, regulatory submissions, or named partner institutions were disclosed. The company website returned only a loading/verification page at the time of scraping, so technical and commercial specifics are not verifiable from the input. No certifications, patents, partnerships, leadership team, customers, or pricing information were available.

No revenue, pricing model, or go-to-motion data were disclosed. The financial figures in the source (EBITDA, operating income, net income reported in the trillions of dollars) are not credible for an 11–50-person startup and appear to be data extraction errors rather than actual reported results; they should not be relied upon. As a result, revenue mechanics, customer segments, and contract economics cannot be characterized with any confidence from this dataset.

Breathe BioMedical firmographics

Firmographics
Name
Breathe BioMedical
Website
https://breathebiomedical.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Breathe BioMedical is a privately held Canadian health-technology company in Moncton that develops a breath-analysis platform for non-invasive cancer screening, currently operating at an early stage with 11–50 employees.
Ownership category
akta.pro rank

Breathe BioMedical industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Breath analysis diagnostics
  • Cancer screening technology
  • Non-invasive diagnostics
  • Biomedical platform
  • Volatile organic compound detection

Where Breathe BioMedical is headquartered

Location

Headquarters

HQ city
Moncton
HQ country
Canada
HQ region
North America

Markets served

Breathe BioMedical business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations

Breathe BioMedical product offering

Product offering

Core offering

Breathe BioMedical is a technology platform that provides cancer screening through breath analysis. The company analyzes breath samples using its proprietary biomedical platform to enable non-invasive detection of cancer, offering an alternative to traditional tissue biopsy or imaging-based screening methods.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cancer Screening via Breath Analysis Platform A technology platform that performs cancer screening by analyzing breath samples, offered to healthcare providers, clinical laboratories, and cancer screening programs as a non-invasive alternative to traditional diagnostic methods.

Companies that use Breathe BioMedical

Customer profile

Ideal customer profiles1 record

Breathe BioMedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Breathe BioMedical competitors and assessment

Company assessment

Emerging players

  • Aethon Medical: Aethon is pursuing breath-based biomarker detection for lung cancer, a direct indication overlap with Breathe BioMedical's cancer-screening focus.
  • Cairn Diagnostics: Cairn Diagnostics develops breath-based diagnostic tests for metabolic and GI conditions, sharing the breath-sample collection and analysis model used by Breathe BioMedical.
  • Bioserenity: Bioserenity focuses on connected diagnostic and monitoring solutions including breath-related respiratory diagnostics, making it a comparable emerging player in non-invasive diagnostic technology.
  • Exhalation Technology (e.g., Sensity AI): Sensity AI applies AI to volatile organic compound (VOC) analysis from breath, sharing the machine-learning-on-breath-signals approach underpinning many cancer-screening platforms.

Broad incumbents

  • GRAIL: GRAIL is the leading multi-cancer early-detection company (Galleri test) and represents the dominant non-invasive screening competitor that any breath-based cancer platform must position against.
  • Thermo Fisher Scientific (Diagnostics): Thermo Fisher's diagnostics segment provides mass spectrometry and lab services that underpin clinical biomarker detection, including breath biomarker workflows; a broad incumbent that could partner with or acquire niche players like Breathe BioMedical.

Direct peers

  • Menssana Research: Menssana Research pioneered clinical breath-testing for disease detection, sharing the core value proposition of non-invasive breath-based diagnostics with Breathe BioMedical.
  • Owlstone Medical: Owlstone Medical is the leading commercial-stage developer of breath-based diagnostics ('Breath Biopsy') for cancer and other diseases, making it the closest direct competitor and most comparable peer to Breathe BioMedical.
  • Xhale: Xhale develops breath-based diagnostic and monitoring technologies, overlapping directly with Breathe BioMedical's breath-analysis modality.
  • Avisa Diagnostics: Avisa is developing breath-based biomarker tests for detecting pulmonary and other infections, directly overlapping with Breathe BioMedical's breath-analysis diagnostic approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Breathe BioMedical social profiles

Digital presence

Breathe BioMedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Breathe BioMedical leadership team

Management profile

Number of profiles

Breathe BioMedical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Breathe BioMedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Breathe BioMedical

What does Breathe BioMedical do?

Breathe BioMedical is a technology platform that provides cancer screening through breath analysis. The company analyzes breath samples using its proprietary biomedical platform to enable non-invasive detection of cancer, offering an alternative to traditional tissue biopsy or imaging-based screening methods.

Is Breathe BioMedical a public or private company?

Breathe BioMedical is a private company. It is classified as unknown and is currently operating.

When was Breathe BioMedical founded?

Breathe BioMedical was founded in 2015. It employs 11 to 50 people.

Where is Breathe BioMedical based?

Breathe BioMedical is headquartered in Moncton, Canada, in the North America region.

Who are Breathe BioMedical's main competitors?

Emerging players on record are Aethon Medical, Cairn Diagnostics, Bioserenity and Exhalation Technology (e.g., Sensity AI). Broad incumbents are GRAIL and Thermo Fisher Scientific (Diagnostics). Direct peers are Menssana Research, Owlstone Medical, Xhale and Avisa Diagnostics.

Does Breathe BioMedical have an API?

No public API is recorded for Breathe BioMedical.

What industry is Breathe BioMedical in?

Breathe BioMedical's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AktienBreathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Nova ScotiaBreathe BioMedical announced that IWK Health's Breast Health Research Unit in Halifax, Nova Scotia, joined as the second Canadian site in its multi-center study on breath analytics for early breast cancer detection. The study compares breath profiles of women with and without breast cancer to identify disease-specific patterns. IWK Health's participation expands the Canadian patient population and strengthens the machine learning algorithm.NewsfileBreathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Nova ScotiaBreathe BioMedical announced IWK Health in Halifax, Nova Scotia, as the second Canadian site in its multi-center study on breath analysis for early breast cancer detection. The study compares breath profiles of women with and without breast cancer, aiming to develop a non-invasive adjunct to mammography. Preliminary analysis from a New Brunswick study showed 88.2% accuracy in differentiating early-stage breast cancer breath signatures.EntrevestorEntrevestorTen startups pitched investors at BioPort Atlantic's Innovator Showcase, marking the conference's 25th year. The three-day event in Halifax featured companies like BioLabMate, ClinicGlide, and Ring Rescue, with pitches covering bioplastics, AI healthcare tools, and medical devices.Global NewsN.B. company’s new breath test could change how breast cancers are detectedMoncton-based Breathe BioMedical has developed a breath test that detects breast cancer by analyzing volatile organic compounds in breath samples, with clinical trials now launched across North America including sites at the Vitalité Health Network in Moncton, with plans to expand to Nova Scotia, Ontario and beyond. The test is currently showing an 88% accuracy rate in identifying cancer patterns and is being offered to patients who have had suspicious mammograms where a biopsy has been ordered. If regulatory approval is obtained, the company aims to begin rolling out the test by 2030 in mobile, fixed, and potentially pharmacy-based settings.BioSpaceBreathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to CanadaVitalité Health Network became the first Canadian site to join Breathe BioMedical's multi-center study on breath-based breast cancer detection. The study, led by Dr. Jocelyne Hébert in Moncton, compares breath profiles of women with and without breast cancer. Preliminary analysis showed 88.2% accuracy in differentiating early-stage cases.NewsfileBreathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to CanadaBreathe BioMedical announced that Vitalité Health Network has joined as the first Canadian site in its multi-center observational study for early breast cancer detection using breath analytics, expanding the study beyond the United States for the first time. The study, led locally in Moncton by Dr. Jocelyne Hébert, will collect breath samples to identify disease-specific patterns that could improve detection for women with dense breast tissue, where mammography has known limitations. Preliminary analysis from a proof-of-concept study in Saint John, New Brunswick showed 88.2% accuracy (92.9% sensitivity, 80.0% specificity) in differentiating breath signatures of women with early-stage breast cancer.FinancialContent Business PageBreathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to CanadaBreathe BioMedical announced that Vitalité Health Network has joined as the first Canadian site in its multi-center observational study for early breast cancer detection using breath analysis. The study, being led locally in Moncton, New Brunswick by Dr. Jocelyne Hébert, will collect breath samples to identify disease-specific patterns in women with dense breast tissue as an adjunct to mammography. Preliminary proof-of-concept analysis showed 88.2% accuracy in differentiating breath signatures between women with early-stage breast cancer and those without.EntrevestorEntrevestorBreathe BioMedical expanded its breast cancer detection device study, adding Weinstein Imaging Associates as the fourth site. A proof-of-concept study showed 88.2% accuracy, with sensitivity of 92.9% and specificity of 80%. The company plans to enroll up to 800 participants across U.S. and Canadian sites.NewsfileBreathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to PittsburghBreathe BioMedical added Weinstein Imaging Associates in Pittsburgh as a clinical site in its multi-center study for a breath test to detect breast cancer in women with dense breasts. Preliminary analysis showed 88.2% accuracy (92.9% sensitivity, 80% specificity) in differentiating early-stage breast cancer breath signatures. The study aims to improve detection as an adjunct to mammography.BioSpaceBreathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to PittsburghBreathe BioMedical added Weinstein Imaging Associates in Pittsburgh as a clinical site for its multi-center study on a breath test for early breast cancer detection. Preliminary analysis showed 88.2% accuracy (92.9% sensitivity, 80% specificity) in distinguishing early-stage breast cancer breath signatures. The study aims to improve detection for women with dense breast tissue, where mammography alone fails in 30-50% of cases.